How to Help Your Patients Save Money on Atogepant: A Provider's Guide to Savings Programs

Atogepant (Qulipta) is a clinically effective migraine preventive, but at approximately $1,185–$1,600 per month without insurance — with no generic alternative available — the financial reality can be a significant barrier to adherence and access. As prescribers, we play a critical role in helping patients navigate these costs.

This guide consolidates the most current savings strategies, assistance programs, and practical approaches for cost-related conversations with patients in 2026.

Understanding the Cost Landscape in 2026

Key pricing facts providers should know when counseling patients:

• Cash price (uninsured): $1,185–$1,600/month for a 30-day supply, regardless of dose strength
• List price (WAC): $1,204.57/month as of January 2026
• Commercial insurance: Typically specialty tier; copay varies. Savings card can reduce to $0/month for eligible patients.
• Medicare Part D: Tier 5 placement typical; ~$250–$300/month coinsurance until $2,000 out-of-pocket cap. LIS patients: ~$9.85/month.
• No generic: Brand-name only; patent challenges eligible since September 2025 but no ANDA approved. No timeline for generic entry.

Strategy 1: Activate the Qulipta Complete Savings Card at Time of Prescribing

The AbbVie Qulipta Complete Savings Card is the most impactful savings tool for commercially insured patients. Building enrollment into your prescribing workflow — rather than leaving it to the patient to discover — significantly improves activation rates.

Key program details for providers:

• Eligible commercially insured patients can pay as little as $0/month (maximum $7,000 savings/year)
• Bridge supply of up to 2 free fills while PA is pending — reduces treatment gaps during the PA waiting period
• Not available for Medicare, Medicaid, TRICARE, or other government insurance patients
• Enrollment: QULIPTASavingsCard.com or 1-855-785-4782; text QULIPTA to 785478

Recommended practice: Have front desk staff or a medical assistant hand patients the savings card information or enrollment QR code at every atogepant prescribing visit. Some EHR systems allow you to print savings card information with the prescription.

Strategy 2: Refer Uninsured/Underinsured Patients to myAbbVie Assist

For patients without insurance or those who cannot afford atogepant despite insurance coverage, AbbVie's myAbbVie Assist Patient Assistance Program may provide Qulipta at no cost. Eligibility is income-based.

• Qualifying patients can receive up to 12 months of medication at no cost, with ability to reapply
• Your signature as the prescriber is required on the application
• Apply at myAbbVieAssist.com or through your AbbVie representative

Strategy 3: Optimize PA Submissions to Reduce Delays and Denials

Every PA denial delays patient access and often triggers an appeal — adding weeks to the process. PA optimization is both a clinical quality initiative and a cost-reduction strategy.

Documentation best practices:

• State exact monthly migraine day count (episodic: 4–14; chronic: ≥15)
• List each prior preventive treatment by name, dose, duration, and specific reason for discontinuation
• Include relevant ICD-10 codes (G43.001–G43.919 for migraine subtypes)
• Use AbbVie's pre-built PA templates at quliptahcp.com to reduce administrative time
• Submit PA and prescription simultaneously — don't wait for one before doing the other

Strategy 4: Help Patients Appeal Insurance Denials

If a patient's PA is denied, they have the legal right to appeal. Your office can support this process significantly:

• Submit a letter of medical necessity with detailed clinical justification
• Request peer-to-peer review with the insurance medical director — these often reverse denials
• File an external appeal through the patient's state insurance commissioner if internal appeals fail

Strategy 5: Medicare Patients — Special Considerations

Medicare patients cannot use the AbbVie manufacturer savings card. For these patients:

• Assess Low Income Subsidy (LIS/Extra Help) eligibility — LIS patients may pay as little as $9.85/month
• Check if the patient's Part D plan has a preferred specialty pharmacy offering lower cost-sharing
• Consider whether a formulary exception is applicable based on clinical need
• Note that starting January 2025, Medicare Part D out-of-pocket costs are capped at $2,000/year — improving affordability for ongoing specialty medications

Strategy 6: Consider Therapeutic Alternatives if Cost Remains Prohibitive

If cost remains a prohibitive barrier after exhausting the above options, therapeutic alternatives within the CGRP class may offer formulary-driven cost advantages for specific patients:

• Nurtec ODT (rimegepant) — another oral gepant; may have different formulary placement with lower copay on some plans
• Injectable CGRP antibodies (erenumab, fremanezumab, galcanezumab) — may be preferred on certain formularies or available as biosimilars at lower cost
• Generic preventives (topiramate, propranolol, amitriptyline) — under $30/month; appropriate bridge therapy when CGRP access is delayed

Drug selection should remain clinically driven, with cost as a secondary consideration — but it's appropriate to discuss cost openly and help patients access the most affordable effective option.

Patient-Facing Resources Providers Can Share

Direct patients to:

• medfinder.com — patient savings guide for atogepant in 2026
• QULIPTASavingsCard.com — enroll in savings card (commercially insured only)
• myAbbVieAssist.com — patient assistance program for uninsured/underinsured
• For providers: medfinder for Providers — real-time pharmacy availability data to reduce patient callbacks about unfilled prescriptions